Nonalcoholic Steatohepatitis (NASH) Clinical Trial
Official title:
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in improvement in their liver disease as measured by changes in the nonalcoholic fatty liver disease (NAFLD) activity score (NAS).
To evaluate whether treatment with obeticholic acid, 25 mg daily for 72 weeks compared to treatment with placebo, improves the severity of nonalcoholic fatty liver disease (NAFLD) as determined from hepatic histology. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04880031 -
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Suspended |
NCT04104321 -
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
|
Phase 3 | |
| Completed |
NCT02891408 -
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT04546984 -
Multiple Dose Safety, Tolerability, PK，PD and Food Effect Study of HEC96719 in Healthy Adult Subjects
|
Phase 1 | |
| Recruiting |
NCT05842512 -
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
|
Phase 2 | |
| Completed |
NCT02854605 -
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT06108219 -
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
|
Phase 2 | |
| Recruiting |
NCT03572465 -
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
|
||
| Active, not recruiting |
NCT05402371 -
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
|
Phase 2 | |
| Terminated |
NCT03823703 -
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT05117489 -
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
Phase 1 | |
| Completed |
NCT04165343 -
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
|
||
| Recruiting |
NCT04913090 -
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06024408 -
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
|
Phase 1 | |
| Terminated |
NCT04004325 -
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
| Completed |
NCT06037577 -
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05320146 -
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
|
||
| Terminated |
NCT00845845 -
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Terminated |
NCT04267393 -
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT04616014 -
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 |